Daxor Announces Duke University Study on Blood Volume Analysis in Heart Failure Published in American Heart Journal

Published Research Demonstrates the Value of BVA in Meeting Key Goal of Identifying Anemia in Heart Failure Patients

Original reporting
Business Insider · markets.businessinsider.com
Published May 14, 2025, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 14, 2025, 12:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Daxor Announces Duke University Study on Blood Volume Analysis in Heart Failure Published in American Heart Journal — source image
Decision brief

The 30-second read

$DXRBullishHigh
01

Why it matters

The Duke University study provides scientific validation, potentially enhancing Daxor's credibility and marketability.

02

Market read

The study could serve as a catalyst for increased adoption of Daxor's technologies, positively influencing stock performance.

03

What to watch

Potential delays in regulatory approval or market acceptance could temper the stock's response.

Relevance 6/10Timing: Immediate, as the news is recent and may influence short-term trading decisions.

Background

Daxor Corporation specializes in blood volume analysis devices, which are used in diagnosing and managing various medical conditions.

Company-level read

Ticker impact

$DXRBullishHigh confidence
Context

The news pertains to Daxor Corporation's study on blood volume analysis, which could influence investor sentiment and valuation.

Expected impact

Moderate upward movement expected in Daxor's stock over the short to medium term.

Evidence & confidence

The study validates Daxor's core technology, potentially leading to increased investor confidence and demand for shares.

Market effects

Potential positive impact on the life sciences sector, especially companies involved in diagnostic technologies.

Primarily affects the U.S. market, given the study's origin and Daxor's primary listing.

Limited, unless Daxor's technology gains widespread adoption internationally.

Counterpoint

The study's findings, while promising, are preliminary and may not lead to immediate commercial adoption, limiting short-term stock movement.

Key entities

  • Daxor Corporation

    A medical device company focusing on blood volume analysis technologies.

  • Duke University

    Research university conducting the study.

  • American Heart Journal

    Journal where the study was published.

Related articles

$DXRMedAI 8/10

Daxor presents clinical data on blood volume analysis technology

Daxor Corporation (DXR) presented clinical data at the Heart Failure Society of America 2026 Annual Scientific Meeting, showing its blood volume analysis (BVA) technology improved patient outcomes in heart failure studies. The BVA system, FDA-cleared with over 95% accuracy, identified fluid issues and guided treatment. The company has operated for 50 years and holds ISO certification.

$DXRMedAI 8/10

Daxor Corporation Receives U.S. Patent for Breakthrough Remote Blood Volume Monitor

Daxor Corporation (Nasdaq: DXR) said the USPTO issued U.S. Patent No. 12,635,917 B2 for a “Remote Blood Volume Monitor.” The patent covers systems for continuous, remote tracking of absolute blood volume after a baseline test by combining Daxor blood-volume algorithms with subsequent hematocrit monitoring, including non-invasive wearable optical sensors (e.g., PPG). Daxor said it targets conditions such as heart failure, syncope, anemia, and polycythemia.

$NNVCMed

NanoViricides, Inc. Has Filed its Quarterly Report - Broad-Spectrum Antiviral Drug NV-387 Oral Gummies Has Entered Two Separate Phase II Clinical Trials - One to Treat Ebola Bundibugyo Virus Disease, and Another to Treat Mpox

NanoViricides, Inc. (NYSE American:NNVC) filed its Q3 2026 report, revealing Phase II trials for NV-387 Oral Gummies to treat Ebola and Mpox. The company has $2.98M in cash and $9.56M in total assets, but warns of insufficient funding for operations beyond November 2027.

$UBERMed

Kohl’s products now available for delivery on Uber Eats

Uber (UBER) and Kohl's (KSS) partnered to offer Kohl's products via Uber Eats, covering 1,100+ U.S. stores. Items include apparel, home goods, and Sephora beauty products. The service launches before the holiday season, with a $10 discount on first orders over $50 until December 3, 2026. Kohl's operates 1,100+ stores in 49 states.

$SPCBMed

SuperCom Wins 2nd Electronic Monitoring Contract in Indiana, Fully Displacing Incumbent Provider

SuperCom (SPCB) won its second electronic monitoring contract in Indiana, replacing an incumbent provider. The deal involves deploying its PureSecurity suite, with rollout starting in December 2026. The company reported a trailing twelve-month EBITDA of approximately $12.1 million through Q3 2026, citing over 50 new U.S. contracts and 20 national project wins in Europe since mid-2024.